BCM
AIM

Bayesian Capital Management’s AIM ImmunoTech AIM Stock Holding History

Bayesian Capital Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-422
Closed -$91K – 733
2020
Q3 		$91K Buy
+422
New +$105K 0.02% 484

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Bayesian Capital Management's AIM Position: Q4 2020 in Review

Bayesian Capital Management sold out of AIM ImmunoTech (AIM) in Q4 2020, closing a stake of 422 shares — an estimated $91K sold.

Bayesian Capital Management first reported a position in AIM in Q3 2020 and held it in 1 quarter. The position peaked at $91K in Q3 2020. 33 funds tracked by Wall St. Rank hold AIM as of Q4 2020.

  • Bayesian Capital Management reported no remaining AIM ImmunoTech position as of Q4 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 422 AIM ImmunoTech shares in Q4 2020, an estimated $91K.
  • Bayesian Capital Management first reported a position in AIM ImmunoTech in Q3 2020 and held it in 1 quarter.
  • Bayesian Capital Management's AIM ImmunoTech position peaked at $91K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2020.

Based on Bayesian Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.